[A clinical study of 31 patients with malignant hematopoietic disease treated with non-T cell-depleted HLA-haploidentical hematopoietic stem cell transplantation].
OBJECTIVE
To investigate the effects and prognosis of malignant hematological disease after HLA haploidentical hematopoietic stem cell transplantation (H-HSCT) without T-cell depletion.


METHODS
The clinical data of 31 cases with malignant hemopoietic disease treated with H-HSCT from July 2002 to July 2006 were analyzed, including 11 cases of standard risk and 20 of high risk.


RESULTS
30 patients achieved engraftment of a median of 13 and 22 days for neutrophil and platelet, with an accumulative incidence of II - IV grade acute graft-versus-host disease (GVHD) 61.3%, and an accumulative incidence of chronic GVHD 41.9%. 13 patients survived with Karnofsky scale over 90.0% after a median follow-up of 24 months. 33 months of accumulative survival was 62.3% in the standard risk group and 35.0% in the high risk group. The CD(3)(+) T cells count of the graft and the disparity of HLA-A, B, DR loci were the major factors of impact on acute GVHD.


CONCLUSIONS
HLA H-HSCT is an effective therapeutic method for malignant hematological disease, CD(3)(+) T cells count of the graft and the disparity of HLA-A, B, DR loci are the major factors of impact on acute GVHD.
Yang
Ming-Zhen
MZ
Department of Hematology, First Affiliated Hospital of Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, China.
Yuan
Yan-Hui
YH
Wu
De-Pei
DP
Chang
Wei-Rong
WR
He
Jun
J
Di
Wen-Ying
WY
D000293:Adolescent; D000328:Adult; D017252:CD3 Complex / Q000032:analysis; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology; D006680:HLA Antigens / Q000032:analysis; D006238:Haploidy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D006650:Histocompatibility Testing; D006801:Humans; D053208:Kaplan-Meier Estimate; D007938:Leukemia / Q000601:surgery*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D019172:Transplantation Conditioning
D017252:CD3 Complex; D006680:HLA Antigens